Page last updated: 2024-08-21

cepharanthine and ER-Negative PR-Negative HER2-Negative Breast Cancer

cepharanthine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Ding, X; Gao, N; Gong, QH; Jia, GF; Jiang, XX; Lei, L; Li, J; Li, ZQ; Shen, LW; Wang, M	1

Other Studies

1 other study(ies) available for cepharanthine and ER-Negative PR-Negative HER2-Negative Breast Cancer

Article	Year
Cepharanthine sensitizes human triple negative breast cancer cells to chemotherapeutic agent epirubicin via inducing cofilin oxidation-mediated mitochondrial fission and apoptosis. Acta pharmacologica Sinica, 2022, Volume: 43, Issue:1 Topics: Actin Depolymerizing Factors; Antineoplastic Agents; Apoptosis; Benzylisoquinolines; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Epirubicin; Humans; Mitochondrial Dynamics; Molecular Structure; Oxidation-Reduction; Structure-Activity Relationship; Triple Negative Breast Neoplasms; Tumor Cells, Cultured	2022

Article

Year

Cepharanthine sensitizes human triple negative breast cancer cells to chemotherapeutic agent epirubicin via inducing cofilin oxidation-mediated mitochondrial fission and apoptosis.

Acta pharmacologica Sinica, 2022, Volume: 43, Issue:1

Topics: Actin Depolymerizing Factors; Antineoplastic Agents; Apoptosis; Benzylisoquinolines; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Epirubicin; Humans; Mitochondrial Dynamics; Molecular Structure; Oxidation-Reduction; Structure-Activity Relationship; Triple Negative Breast Neoplasms; Tumor Cells, Cultured

2022